SUVEN PHARMA
CSIR-IICT and SUVEN Pharmaceuticals Ltd., joined hands for the process technology transfer and manufacture of anti COVID drugs Molnupiravir and 2-DG
HYDERABAD, INDIA (10 June’ 2021) Suven Pharmaceuticals Ltd., (SPL), CSIR-Indian Institute of Chemical Technology, Hyderabad and CSIR-National Institute of Interdisciplinary Science & Technology, Thiruvananthapuram have entered into an agreement for the process technology transfer and manufacturing of the anti COVID drug, Molnupiravir and 2-DG. It is a related party transaction as one of our Independent Directors Dr S Chandrasekhar is the Director of CSIR-IICT, Hyderabad. The agreements between the parties involve a total fee of Rs 8 lakh plus taxes for the grant of the licenses on non-exclusive basis to SPL.
Molnupiravir, the antiviral drug was initially developed for the treatment of influenza and is repurposed to completely suppress the COVID virus transmission within 24 hours according to the study recently published in the journal Nature Microbiology. The drug could be a game changer in mitigation of SARS-CoV-2 virus.
The synthetic process know how for Molnupiravir was sourced from CSIR-NIIST and scale up process was successfully carried out by CSIR-IICT. The complete technology know how will be transferred and SPL in turn will manufacture and launch in the domestic market as an effective medication for COVID infected patients subject to regulatory approvals.
As per the agreement, CSIR IICT also would provide the process know how for the manufacture of new anti COVID drug 2-DG to treat moderately and severely COVID infected patients to reduce their oxygen dependency
NMDC
Shri Vineet Pandey, CVO, SAIL has taken over additional charge of Chief Vigilance Officer (CVO), NMDC Ltd. He is an officer belonging to 1994 batch of Indian Railways Service of Electrical Engineers (IRSEE)
Having worked in prestigious organisations such as Indian Railways, SAIL, RITES and Central Electricity Authority, he brings in vast experience in Corporate Coordination, Maintenance of Probity & Integrity, Project Engineering, System Integration, Production & Maintenance of Electrical Rolling Stock, Energy Management and Green-energy Initiatives etc
He is a Graduate in Electrical Engineering from Malviya National
Institute of Technology, Jaipur. He has attended management training
modules at ICLIF/Kuala-Lumpur, INSEAD/Singapore and ISB/Mohali. In
addition to his present assignment as CVO, SAIL, he will have additional
charge of CVO, NMDC Ltd.
GRASIM
Birla Cellulose’s Grasim Vilayat Site Achieves the EU BAT Compliances
Birla Cellulose’s Grasim Cellulosic Division, Vilayat, India has successfully commissioned the Carbon-disulphide Adsorption Plant (CAP) and has achieved the stringent level of sulphur-toair emission norms stipulated in the EU BAT references (EU Best Available Technologies BREFs) for the viscose manufacturing process.
This initiative is in line with Birla Cellulose's aim to apply the best available technologies (EU BAT) at all of its fibre locations and investments of $170 million are in progress in order to achieve this by the end of 2022
“Adapting the best available technologies is an important milestone towards achieving global leadership in sustainable practices in the MMCF industry”, informed Mr H K Agrawal, Chief Operating Officer of Birla Cellulose, “we are investing in innovation to continually improve our performance. This is the reason that our products come with sustainability credentials that are global benchmarks.” Birla Cellulose has already achieved Carbon Neutrality in Scope 1 & 2 emissions by sequestration of carbon in its managed forests. Birla Cellulose is also ranked #1 in Canopy’s Hot Button Report for its sustainable forestry practices and innovations in NextGen solutions. Birla Cellulose has also established the global benchmark for lowest water intensity in the viscose manufacturing.
Grasim Vilayat has installed state-of-the-art closed-loop technologies to recover and recycle CS2, which is the key raw material for viscose manufacturing process. With these technologies, the site is able to significantly reduce its emissions and achieve 90-95% recovery in terms of sulphur and recycle it back to the process. In addition to this, the site also meets all other EU BAT parameters. This was confirmed by an audit conducted by Sustainable Textile Solutions, UK (STS) recently. The site also meets the ZDHC MMCF responsible viscose production standards.
Vilayat is one of Birla Cellulose's flagship sites and post the ongoing expansion, it will be the world's largest MMCF manufacturing site. The on-going expansion project at Vilayat site is also designed to comply with EU BAT requirements and designed to achieve low energy consumption.
The Vilayat will supply eco-enhanced fibres, Livaeco by Birla Cellulose™ (Viscose & Modal variants) to sustainability conscious Brands globally. Livaeco by Birla CelluloseTM range of products comes with outstanding sustainability credentials such as EU BAT norms, FSC® certification, low water and energy consumption and complete supply chain traceability from forest-to-fashion using GreenTrack™ platform
COSMO FILMS
Cosmo Specialty Chemicals, a 100% subsidiary of Cosmo Films Ltd. Launches Fabritizer - An After-Wash Laundry Sanitizer For 7 Days Protection From Germs and Viruses
: Cosmo Specialty Chemicals, a 100% subsidiary of Cosmo Films Limited, a global leader in packaging films and synthetic paper, forays into the Fast Moving Consumer Goods industry with the launch of Fabritizer, an after-wash laundry sanitizer for germ-free clothing. Forming a unique protective layer that stays up to 7 days even after ironing, Fabritizer kills 99.9% viruses, germs and bacteria and is AATCC 100: 2012 and 2019 Standard certified (tested at a Mumbai lab), making it a superior product in the market. It also gives protection against human Covid viruses (tested as per ISO 18184 standards at a Lab in USA).
Live on Amazon India on 3 rd of June 2021, Fabritizer will be available on e-commerce giants including Flipkart and soon be launched on its own e-commerce platform across India. Skinfriendly and ideal for bed linens, towels, baby clothing, innerwear etc., FABRITIZER is compatible with all detergents as well as machine and hand laundry and works in both hot and cold water. Free from Silver Technology and Phosphate, the product retains its effectiveness against odour causing germs and maintains a soothing and long-lasting fresh fragrance.
Talking about the product, Mr. Pankaj Poddar, Director, Cosmo Specialty Chemicals Private Limited and CEO, Cosmo Films Limited, says, “This product can be a game changer for tackling the current situation of Covid. And just by following small necessary steps like using sanitizer, washing hands and now using Fabritizer for washing your clothes can make a huge impact on the current situation and as a society, we can overcome this pandemic by taking proper precautions and by following all necessary steps.”
High quality and safe, Fabritizer is available for Rs. 299 for 480 ml and Rs. 499 for 960 ml on Amazon and Flipkart from 3rd of June 2021 onwards.
Alkem launches Perampil (Perampanel Tablets) at affordable prices and improved patient access for epilepsy treatment in India
Perampanel is a broad spectrum anti-epileptic drug (AED) with novel mode of action by acting as a noncompetitive AMPA receptor antagonist1
and convenient dosing of once daily oral administration2.
On June 9, 2021 Alkem has launched brand Perampil containing Perampanel at affordable prices to
make the treatment accessible to the Indian population.
Alkem Laboratories Ltd. (Alkem), one of the India’s leading pharmaceutical formulation development, manufacturing, and marketing companies, announces the launch of Perampil (Perampanel) tablets 2 mg/4 mg/6 mg on June 9th 2021 to make the treatment accessible to patients and healthcare providers improving their quality of life. Alkem has launched Perampil, at 2 mg – Rs. 49/strip of 7 tablets, 4 mg – Rs. 180/strip of 15 tablets and 6 mg – Rs. 300/strip of 15 tablets, to improve patient access.
This product reaffirms Alkem’s commitment towards improving epilepsy care by bringing multiple treatment options of quality products to patients and health care professionals in India. Alkem had also launched Brivasure (Brivaracetam) tablets in March 2021 for the adjunctive management of partial onset seizure with or without secondary generalization
The drug, Perampanel, has been approved by the Drugs Controller General of India (DCGI), as an adjunctive therapy in treatment of partial onset seizures in patients with epilepsy aged 4 years and older and also as an adjunctive therapy in treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. Alkem continues to work persistently towards the production of top-quality products to improve patient access and quality of life for them.